Acción SCYX SCYNEXIS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas SCYNEXIS, Inc.

Acciones

SCYX

US8112922005

Tiempo real estimado Cboe BZX
Otros sitios de cotización
 17:33:20 15/05/2024 		Varia. Cinco días. Varia. 1 de enero.
2,065 USD +4,82 % Gráfico intradía de SCYNEXIS, Inc. +11,41 % -8,07 %
08/05 SCYNEXIS, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
09/04 SCYNEXIS, Inc. presentará datos preclínicos sobre el fungerp de segunda generación SCY-247 en el 34º Congreso Europeo de Microbiología Clínica y Enfermedades Infecciosas CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M
Scynexis: Q1 Earnings Snapshot
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
SCYNEXIS, Inc. Presents Preclinical Data on Second Generation Fungerp SCY-247 Against Mucormycosis At the 11Th Advances Against Aspergillosis and Mucormycosis Conference
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
SCYX DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX
SCYX Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
SCYNEXIS Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción SCYX
  4. Noticias SCYNEXIS, Inc.
  5. Otros idiomas